Revealing the inhibitory effect of VASH1 on ovarian cancer from multiple perspectives

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• The role of Vasohibin-1 (VASH1) in human cancers remains largely unexamined.
• Previous research has not comprehensively evaluated VASH1's function across diverse cancer types.

Purpose of the Study:

• To investigate the tumor suppressor role of VASH1 in human cancers, including epithelial ovarian tumors.
• To explore VASH1's regulatory impact on clinical prognosis, diagnosis, tumor purity, and immune cell infiltration.
• To elucidate the anti-tumor mechanisms of VASH1 in ovarian cancer.

Main Methods:

• Comparative analysis of VASH1 expression in pancancer and non-tumorous tissues using public databases.
• Functional enrichment analysis, drug sensitivity assays, and phenotypic experiments in ovarian cancer models.
• In vivo experiments to validate VASH1's effect on malignant phenotypes.

Main Results:

• VASH1 expression is significantly lower in neoplastic tissues compared to normal tissues across multiple cancer types.
• Reduced VASH1 expression is associated with poorer overall survival (OS) and recurrence-free survival (RFS).
• VASH1 negatively regulates tumor purity and influences the tumor microenvironment via immunocyte infiltration, acting as a biomarker for chemotherapy efficacy in ovarian cancer.

Conclusions:

• Vasohibin-1 (VASH1) functions as a tumor suppressor by regulating the extracellular matrix receptor pathway.
• VASH1 demonstrates potential as a diagnostic biomarker and a therapeutic target for inhibiting cancer progression, particularly in ovarian cancer.
• VASH1's ability to inhibit the malignant phenotype in vivo highlights its therapeutic promise.